INBRAIN Neuroelectronics, a Barcelona-based company developing graphene-based brain-computer interface therapeutics (BCI-Tx), has announced a strategic collaboration with the Mayo Clinic to advance its precision neurotechnology platform for patients with unmet needs in neurological disorders. The partnership is built on a non-exclusive know-how exchange, enabling INBRAIN and Mayo Clinic experts to conduct hands-on evaluations of INBRAIN’s investigational BCI-Tx platform in IRB-approved clinical settings. The goal is to accelerate the generation of high-quality, real-world evidence to support the platform’s development and eventual commercialization. “Our goal is to translate the unique performance of graphene and AI to deliver tangible benefits for patients and clinicians,” said Carolina Aguilar, CEO and Co-Founder of INBRAIN Neuroelectronics. “With Mayo Clinic’s deep clinical expertise, alongside other leading academic centers in the U.S. and Europe, we aim to validate our platform within real-world workflows, speed up evidence generation, and responsibly advance toward patient-focused BCI therapeutics.” As part of its global expansion, INBRAIN is establishing a U.S. subsidiary with planned offices in Boston and on the West Coast. The Boston site will serve as a central hub for clinical trials in the United States and lay the foundation for commercialization and therapeutic expansion beyond Parkinson’s disease. The company continues to maintain its global headquarters and core R&D operations in Barcelona. INBRAIN is also advancing scalable manufacturing processes for its graphene-based BCI systems, a critical step toward enabling broader clinical use and global commercial adoption. To date, the company has raised $124 million in funding from a global coalition of medtech and deep tech investors, including Aliath Bioventures, Asabys Partners, CDTI, the Catalan Government (Avançsa & ICF), FondICO, Graybella Capital, IMECXpand, the European Innovation Council, Truventuro, Vsquared Ventures, and Mayo Clinic. Mayo Clinic has a financial interest in the technology discussed in this announcement. Any revenue generated will be reinvested into the clinic’s not-for-profit mission of advancing patient care, education, and research. INBRAIN Neuroelectronics is at the forefront of real-time precision neurology, developing the world’s first graphene-based BCI-Tx platform. The technology integrates high-precision neural decoding with micrometric stimulation to deliver adaptive, personalized treatments for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. By enabling continuous monitoring and autonomous therapy adjustments, the AI-driven platform enhances treatment efficacy while reducing side effects. Through collaborations with Merck KGaA and its subsidiary INNERVIA Bioelectronics, INBRAIN is also expanding its solutions into peripheral nerve and systemic disease applications, broadening the potential of neurotechnology and bioelectronics. For more information, visit www.inbrain-neuroelectronics.com and follow the company on LinkedIn.